. Author manuscript; available in PMC: 2014 Aug 1.

Published in final edited form as: Cancer Res. 2013 Jun 17;73(15):4801–4809. doi: 10.1158/0008-5472.CAN-12-3273

Table 3.

Serum miRNA 17-marker risk score associated with 2-year survival in patients with advanced NSCLC from the study population recruited at the University of Texas MD Anderson Cancer Center between 2002 and 2009.

	Risk score	2-Year Death, n%	2-Year Survival, n%	Adjusted HR^a (95% CI)	P	MST
Training Set	Low	37 (64.9)	20 (35.1)	1(reference)	0.002	14.3
Training Set	High	56 (100.0)	0 (0.0)	2.18 (1.32–3.59)	0.002	7.8

Testing Set	Low	42 (62.7)	25 (37.3)	1(reference)	8.0 × 10⁻⁵	17.4
Testing Set	High	52 (100.0)	0 (0.0)	2.71 (1.65–4.45)	8.0 × 10⁻⁵	7.6

Combined Set	Low	79 (63.7)	45 (36.3)	1(reference)	1.1 × 10⁻⁷	15.6
Combined Set	High	108 (100.0)	0 (0.0)	2.46 (1.77–3.44)	1.1 × 10⁻⁷	7.8

Adjusted for age, sex, smoking status, clinical stage, and treatment regimen.